Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment

References

• Barten M. J., van Gelder T., Gummert J. F., Boeke K., Shorthouse R., Billingham M. E., et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002; 2: 719–32
   PubMed Web of Science ®Google Scholar
• Allison A. C., Eugui E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118
   PubMed Web of Science ®Google Scholar
• Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double‐blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39–47
   PubMed Web of Science ®Google Scholar
• Remuzzi G., Lesti M., Gotti E., Ganeva M., Dimitrov B. D., Ene‐Iordache B., et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364: 503–12
   PubMed Web of Science ®Google Scholar
• van Gelder T., Hilbrands L. B., Vanrenterghem Y., Weimar W., de Fijter J. W., Squifflet J. P., et al. A randomized double‐blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261–6
   PubMed Web of Science ®Google Scholar
• Franklin T. J., Cook J. M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515–24
   PubMed Web of Science ®Google Scholar
• Glander P., Braun K. P., Hambach P., Bauer S., Mai I., Roots I., et al. Non‐radioactive determination of inosine 5′‐monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34: 543–9
   PubMed Web of Science ®Google Scholar
• Albrecht W., Storck M., Pfetsch E., Martin W., Abendroth D. Development and application of a high‐performance liquid chromatography‐based assay for determination of the activity of inosine 5'‐monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000; 22: 283–94
   PubMed Web of Science ®Google Scholar
• Griesmacher A., Weigel G., Seebacher G., Muller M. M. IMP‐dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997; 43: 2312–7
   PubMed Web of Science ®Google Scholar
• Montero C., Duley J. A., Fairbanks L. D., McBride M. B., Micheli V., Cant A. J., et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin‐treated patients using a high performance liquid chromatography linked method. Clina Chim Acta 1995; 238: 169–78
   PubMed Web of Science ®Google Scholar
• Glander P., Hambach P., Braun K. P., Fritsche L., Waiser J., Mai I., et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long‐term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470–6
   PubMed Web of Science ®Google Scholar
• Weigel G., Griesmacher A., Zuckermann A. O., Laufer G., Mueller M. M. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001; 69: 137–44
   PubMed Web of Science ®Google Scholar
• Sanquer S., Breil M., Baron C., Dhamane D., Astier A., Lang P. Induction of inosine monophosphate dehydrogenase activity after long‐term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65: 640–8
   PubMed Web of Science ®Google Scholar
• Langman L. J., LeGatt D. F., Halloran P. F., Yatscoff R. W. Pharmacodynamic assessment of mycophenolic acid‐induced immunosuppression in renal transplant recipients. Transplantation 1996; 62: 666–72
   PubMed Web of Science ®Google Scholar
• Mandla R., Line P. D., Midtvedt K., Bergan S. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 2003; 25: 407–14
   PubMed Web of Science ®Google Scholar
• Bergan S. TDM: Report concentration, Css, rather than area under the curve, AUC. Ther Drug Monit 2003; 25: 743
   PubMed Web of Science ®Google Scholar
• Weber L. T., Shipkova M., Armstrong V. W., Wagner N., Schutz E., Mehls O., et al. The pharmacokinetic‐pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759–68
   PubMed Web of Science ®Google Scholar
• Cattaneo D., Gaspari F., Ferrari S., Stucchi N., Del Priore L., Perico N., et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001; 15: 402–9
   PubMed Web of Science ®Google Scholar
• Filler G., Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22: 169–73
   PubMed Web of Science ®Google Scholar
• Mourad M., Malaise J., Chaib E. D., De Meyer M., Konig J., Schepers R., et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88–94
   PubMed Web of Science ®Google Scholar
• Jain J., Almquist S. J., Ford P. J., Shlyakhter D., Wang Y., Nimmesgern E., et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004; 67: 767–76
   PubMed Web of Science ®Google Scholar
• Dayton J. S., Lindsten T., Thompson C. B., Mitchell B. S. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994; 152: 984–91
   PubMed Web of Science ®Google Scholar
• Escobar‐Henriques M., Daignan‐Fornier B. Transcriptional regulation of the yeast GMP synthesis pathway by its end products. J Biol Chem 2001; 276: 1523–30
   PubMed Web of Science ®Google Scholar
• Grinyo J. M., Gil‐Vernet S., Cruzado J. M., Caldes A., Riera L., Seron D., et al. Calcineurin inhibitor‐free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003; 16: 820–7
   PubMed Web of Science ®Google Scholar
• Glander P., Hambach P., Braun K. P., Fritsche L., Giessing M., Mai I., et al. Pre‐transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4: 2045–51
   PubMed Web of Science ®Google Scholar
• Quemeneur L., Gerland L. M., Flacher M., Ffrench M., Revillard J. P., Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 2003; 170: 4986–95
   PubMed Web of Science ®Google Scholar